{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:11:46Z","timestamp":1792087906583,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41591-019-0476-5","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T12:03:12Z","timestamp":1559822592000},"page":"936-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":304,"title":["Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijoyesh","family":"Mookerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razi","family":"Ghori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Homet","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nageatte","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"476_CR1","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med.\n\t\t\t\t\t371, 1867\u20131876 (2014).","journal-title":"N. Engl. J. Med."},{"key":"476_CR2","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med.\n\t\t\t\t\t371, 1877\u20131888 (2014).","journal-title":"N. Engl. J. Med."},{"key":"476_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med.\n\t\t\t\t\t372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"476_CR4","doi-asserted-by":"publisher","first-page":"e1052212","DOI":"10.1080\/2162402X.2015.1052212","volume":"5","author":"B Homet Moreno","year":"2016","unstructured":"Homet Moreno, B., Mok, S., Comin-Anduix, B., Hu-Lieskovan, S. & Ribas, A. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology\n\t\t\t\t\t5, e1052212 (2016).","journal-title":"Oncoimmunology"},{"key":"476_CR5","doi-asserted-by":"publisher","first-page":"e1238557","DOI":"10.1080\/2162402X.2016.1238557","volume":"5","author":"MA Deken","year":"2016","unstructured":"Deken, M. A. et al. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology\n\t\t\t\t\t5, e1238557 (2016).","journal-title":"Oncoimmunology"},{"key":"476_CR6","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF\n\t\t\t\t\tV600E melanoma. Sci. Transl. Med.\n\t\t\t\t\t7, 279ra41 (2015).","journal-title":"Sci. Transl. Med."},{"key":"476_CR7","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani, R. et al. Genomic classification of cutaneous melanoma. Cell\n\t\t\t\t\t161, 1681\u20131696 (2015).","journal-title":"Cell"},{"key":"476_CR8","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med.\n\t\t\t\t\t364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"476_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet\n\t\t\t\t\t380, 358\u2013365 (2012).","journal-title":"Lancet"},{"key":"476_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med.\n\t\t\t\t\t366, 207\u2013215 (2012).","journal-title":"N. Engl. J. Med."},{"key":"476_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMc1302338","volume":"368","author":"A Ribas","year":"2013","unstructured":"Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med.\n\t\t\t\t\t368, 1365\u20131366 (2013).","journal-title":"N. Engl. J. Med."},{"key":"476_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0181","volume":"2","author":"LJ Vella","year":"2014","unstructured":"Vella, L. J. et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol. Res.\n\t\t\t\t\t2, 351\u2013360 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"476_CR13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long, G. V. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol.\n\t\t\t\t\t29, 1239\u20131246 (2011).","journal-title":"J. Clin. Oncol."},{"key":"476_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov.\n\t\t\t\t\t4, 80\u201393 (2014).","journal-title":"Cancer Discov."},{"key":"476_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov.\n\t\t\t\t\t4, 94\u2013109 (2014).","journal-title":"Cancer Discov."},{"key":"476_CR16","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest.\n\t\t\t\t\t127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"476_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature\n\t\t\t\t\t515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"476_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science\n\t\t\t\t\t348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"476_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell\n\t\t\t\t\t165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"476_CR20","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol.\n\t\t\t\t\t34, 4102\u20134109 (2016).","journal-title":"J. Clin. Oncol."},{"key":"476_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","volume":"18","author":"JS Wilmott","year":"2012","unstructured":"Wilmott, J. S. et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res.\n\t\t\t\t\t18, 1386\u20131394 (2012).","journal-title":"Clin. Cancer Res."},{"key":"476_CR22","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","volume":"19","author":"DT Frederick","year":"2013","unstructured":"Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res.\n\t\t\t\t\t19, 1225\u20131231 (2013).","journal-title":"Clin. Cancer Res."},{"key":"476_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov.\n\t\t\t\t\t6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"476_CR24","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","volume":"23","author":"RE Vilain","year":"2017","unstructured":"Vilain, R. E. et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin. Cancer Res.\n\t\t\t\t\t23, 5024\u20135033 (2017).","journal-title":"Clin. Cancer Res."},{"key":"476_CR25","unstructured":"K\n\t\t\t\t\tEYTRUDA\n\t\t\t\t\t\n\t\t\t\t\t\t\u00ae\n\t\t\t\t\t\n\t\t\t\t\t(Pembrolizumab) for Injection, for Intravenous Use (Merck Sharp & Dohme Corp., 2019)."},{"key":"476_CR26","unstructured":"T\n\t\t\t\t\tafinlar 50 mg Hard Capsules (Novartis Europharm, 2015)."},{"key":"476_CR27","unstructured":"M\n\t\t\t\t\tEKINIST (Trametinib) Tablets, for Oral Use (GlaxoSmithKline, 2018)."},{"key":"476_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","volume":"82","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf, D. et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur. J. Cancer\n\t\t\t\t\t82, 45\u201355 (2017).","journal-title":"Eur. J. Cancer"},{"key":"476_CR29","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med.\n\t\t\t\t\t372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"476_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med.\n\t\t\t\t\t377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"476_CR31","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter, J. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet\n\t\t\t\t\t390, 1853\u20131862 (2017).","journal-title":"Lancet"},{"key":"476_CR32","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/jco.2015.33.15_suppl.3003","volume":"33","author":"A Ribas","year":"2015","unstructured":"Ribas, A. et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and\/or MEK (trametinib) inhibitors in advanced melanoma. J. Clin. Oncol.\n\t\t\t\t\t33, 3003 (2015).","journal-title":"J. Clin. Oncol."},{"key":"476_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/sj.jidsp.5640233","volume":"4","author":"S Lyle","year":"1999","unstructured":"Lyle, S. et al. Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J. Investig. Dermatol. Symp. Proc.\n\t\t\t\t\t4, 296\u2013301 (1999).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"476_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1600-0560.1999.tb01824.x","volume":"26","author":"JD Nuckols","year":"1999","unstructured":"Nuckols, J. D., Shea, C. R., Horenstein, M. G., Burchette, J. L. & Prieto, V. G. Quantitation of intraepidermal T-cell subsets in formalin-fixed, paraffin-embedded tissue helps in the diagnosis of mycosis fungoides. J. Cutan. Pathol.\n\t\t\t\t\t26, 169\u2013175 (1999).","journal-title":"J. Cutan. Pathol."},{"key":"476_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods\n\t\t\t\t\t12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"476_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics\n\t\t\t\t\t31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"476_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","volume":"8","author":"CS Grasso","year":"2018","unstructured":"Grasso, C. S. et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov.\n\t\t\t\t\t8, 730\u2013749 (2018).","journal-title":"Cancer Discov."},{"key":"476_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature\n\t\t\t\t\t487, 239\u2013243 (2012).","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1038\/s41591-019-0535-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0476-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0476-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0476-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:59:32Z","timestamp":1684605572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-019-0476-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1038\/s41591-019-0476-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"24 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This sentence was originally included in the legend for Extended Data Fig. 1: \"*Nominal time after first dose. N denotes number of patients with samples for pharmacokinetic analysis.\" The sentence was deleted as no asterisk appeared in that figure.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R. received personal fees for consulting from Amgen, Bristol-Myers Squibb, Chugai, Genentech\u2013Roche, Merck\u2013MSD and Novartis, and is on the scientific advisory board of, and holds stock in, Advaxis, Apricity, Arcus, Bioncotech, Compugen, CytomX, Five Prime, FLX Bio, ImaginAb, Isoplexis, Kite-Gilead, Merus, Rgenix, Lutris, PACT Pharma and Tango Therapeutics. V.A. received personal fees and non-financial support from Bristol-Myers Squibb and Merck Sharpe & Dohme, and personal fees only from Merck Serono, Novartis and Pierre Fabre. W.H.M. received personal fees from Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Amgen and Roche. M.S.C. received personal fees from Merck Sharpe & Dohme, Novartis, Bristol-Myers Squibb and Pierre Fabre. R.F. received personal fees from Merck Sharpe & Dohme. G.V.L. received personal fees from Aduro, Amgen, Array, Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, Oncosec and Pierre Fabre. F.S.H. reports receiving personal fees from Merck, Bristol-Myers Squibb, EMD Serono, Celldex, Sanofi, and Novartis; other from Merck to his institution and he has a patent on MICA related disorders for which he receives royalties. B.M. reports employment and stock options at Novartis and stock options at GlaxoSmithKline. B.H.M., Q.Z., R.G. and N.I. report employment at Merck Sharp & Dohme. N.I. also holds stocks in Merck & Co. and GlaxoSmithKline. O.H. reports personal fees from Merck, during the conduct of the study; personal fees from Amgen, Novartis, Roche, Bristol-Myers Squibb, Genenetch, and contracted institutional support from AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech, Immunocore, Incyte, Merck, MerckSerono, MedImmune, Novartis, Pfizer, Rinat and Roche. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}